EGFR and lung adenocarcinoma: reported no significant difference in recurrence-free survival between patients with and without adjuvant UFT in pathologically high-risk stage I EGFR-positive lung adenocarcinoma, particularly T1c/T2a or those with lymphovascular invasion [13] However, they found a benefit of UFT in the EGFR mutation-negative group in contrast to the results of this study.